4880B586-BA92-48B2-A233-5C245D2E31C0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 63.83048620236531
- age_years
- 29
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.533
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.479
- MYC_TARGETS_V1+0.472
- TGF_BETA_SIGNALING+0.470
- INTERFERON_ALPHA_RESPONSE+0.468
- G2M_CHECKPOINT+0.461
- DNA_REPAIR+0.447
- E2F_TARGETS+0.424
- IL6_JAK_STAT3_SIGNALING+0.401
Top 10 suppressed
- KRAS_SIGNALING_DN-0.404
- PANCREAS_BETA_CELLS-0.388
- SPERMATOGENESIS-0.329
- MYOGENESIS-0.312
- ESTROGEN_RESPONSE_EARLY-0.179
- ESTROGEN_RESPONSE_LATE-0.145
- ANDROGEN_RESPONSE-0.092
- APICAL_SURFACE-0.088
- ANGIOGENESIS-0.060
- BILE_ACID_METABOLISM-0.059
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 15838786-D895-4F63-88A9-BDE627AE7958 | — | — | 0.945 |
| 2 | 63E967C4-863F-4253-ADFE-3CDC13B6187A | — | — | 0.944 |
| 3 | C8955D29-D8EE-4F68-AEAC-CE1B838B22BF | — | — | 0.939 |
| 4 | 0108A1FA-9CBF-4CF6-8981-7FB39C39B335 | — | — | 0.934 |
| 5 | 27C775C6-ABAD-44BE-B995-21DC4C68C399 | — | — | 0.927 |
| 6 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.927 |
| 7 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.924 |
| 8 | A541B123-A51C-4EF0-839E-8A9513311C98 | — | — | 0.919 |
| 9 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.918 |
| 10 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.533 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.479 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.472 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.468 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.461 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.447 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.424 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.401 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.398 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.396 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.369 | Inavolisib | — uncovered |
| APOPTOSIS | 0.341 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.319 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.277 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.265 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.264 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.258 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.252 | Inavolisib | — uncovered |